Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorAurelio Maggioen_US
dc.contributor.authorAngela Vitranoen_US
dc.contributor.authorGiuseppina Calvarusoen_US
dc.contributor.authorRita Baroneen_US
dc.contributor.authorPaolo Riganoen_US
dc.contributor.authorLuigi Mancusoen_US
dc.contributor.authorLiana Cucciaen_US
dc.contributor.authorMarcello Capraen_US
dc.contributor.authorLorella Pitroloen_US
dc.contributor.authorLuciano Prossomaritien_US
dc.contributor.authorAldo Filosaen_US
dc.contributor.authorVincenzo Carusoen_US
dc.contributor.authorCalogera Gerardien_US
dc.contributor.authorSaveria Campisien_US
dc.contributor.authorPaolo Cianciullien_US
dc.contributor.authorAndroulla Elefteriouen_US
dc.contributor.authorMichel Angastiniotisen_US
dc.contributor.authorHala Hamzaen_US
dc.contributor.authorPaul Telferen_US
dc.contributor.authorJohn Malcolm Walkeren_US
dc.contributor.authorArintaya Phrommintikulen_US
dc.contributor.authorNipon Chattipakornen_US
dc.description.abstractCardiac damage remains a major cause of mortality among patients with thalassemia major. The detection of a lower cardiac magnetic resonance T2* (CMR-T2*) signal has been suggested as a powerful predictor of the subsequent development of heart failure. However, the lack of worldwide availability of CMR-T2* facilities prevents its widespread use for follow-up evaluations of cardiac function in thalassemia major patients, warranting the need to assess the utility of other possible procedures. In this setting, the determination of left ventricular ejection fraction (LVEF) offers an accurate and reproducible method for heart function evaluation. These findings suggest a reduction in LVEF ≥ 7%, over time, determined by 2-D echocardiography, may be considered a strong predictive tool for the detection of thalassemia major patients with increased risk of cardiac death. The reduction of LVEF ≥ 7% had higher (84.76%) predictive value. Finally, Kaplan-Meier survival curves of thalassemia major patients with LVEF ≥ 7% showed a statistically significant decreased probability of survival for heart disease (p = 0.0022). However, because of limitations related to the study design, such findings should be confirmed in a large long-term prospective clinical trial. © 2012 Elsevier Inc.en_US
dc.subjectBiochemistry, Genetics and Molecular Biologyen_US
dc.titleSerial echocardiographic left ventricular ejection fraction measurements: A tool for detecting thalassemia major patients at risk of cardiac deathen_US
article.title.sourcetitleBlood Cells, Molecules, and Diseasesen_US
article.volume50en_US Ematologia IIen_US degli Studi di Palermoen_US Medicina Trasfusionaleen_US Franco e Piera Cutinoen_US Pediatria IIen_US Regionale per la Cura delle Microcitemieen_US Pediatria A.O. Cardarellien_US Garibaldien_US Talassemiaen_US Centro Microcitemiaen_US SantEugenioen_US Microcitemia A.O. Perrinoen_US International Foundationen_US Universityen_US and The London Queen Mary's School of Medicine and Dentistryen_US Brompton and Harefield NHS Trusten_US Mai Universityen_US
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.